Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Jörg TrojanPatrick MollonBruno DanieleFlorence MarteauLidia MartínYuxin LiQing XuPiscaglia FabioRenata ZauchaDebashis SarkerHo Yeong LimMarino VeneritoPublished in: Advances in therapy (2021)
Clinical trials.gov identifiers: CELESTIAL trial (NCT01908426) and REACH-2 trial (NCT02435433). These slides can be retrieved under Electronic Supplementary Material.